These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35304710)

  • 1. The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors.
    Mullally WJ; Greene J; Jordan EJ; Horgan AM; O'Connor M; Calvert PM
    Ir J Med Sci; 2023 Feb; 192(1):83-87. PubMed ID: 35304710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade.
    Li S; Zou J; Liu C; Jiao X; Gong J; Li J; Wang Z; Lu M; Lu Z; Shen L
    Clin Immunol; 2020 Mar; 212():108345. PubMed ID: 31953149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
    Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
    BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
    Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
    Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
    Front Oncol; 2022; 12():951985. PubMed ID: 36387152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
    Cox S; Hurt C; Grenader T; Mukherjee S; Bridgewater J; Crosby T
    Radiother Oncol; 2017 Oct; 125(1):154-159. PubMed ID: 28893415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
    Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
    Br J Cancer; 2016 Mar; 114(6):612-5. PubMed ID: 26889974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    Li L; Ai L; Jia L; Zhang L; Lei B; Zhang Q
    BMC Cancer; 2022 Jan; 22(1):29. PubMed ID: 34980025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Lim JU; Kang HS; Yeo CD; Kim JS; Park CK; Kim JW; Kim SJ; Lee SH
    J Thorac Dis; 2021 May; 13(5):2824-2832. PubMed ID: 34164174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
    Wood G; Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
    Anticancer Drugs; 2017 Jun; 28(5):546-550. PubMed ID: 28252533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
    Ferrucci PF; Ascierto PA; Pigozzo J; Del Vecchio M; Maio M; Antonini Cappellini GC; Guidoboni M; Queirolo P; Savoia P; Mandalà M; Simeone E; Valpione S; Altomonte M; Spagnolo F; Cocorocchio E; Gandini S; Giannarelli D; Martinoli C
    Ann Oncol; 2016 Apr; 27(4):732-8. PubMed ID: 26802161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
    Ogul A; Kidi MM; Buyuksimsek M
    J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
    van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
    Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.